CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,899 enrolled
Drug / intervention
tiotropium +2 moredrug
Likely dose
Tiotropium Respimat 1.25 mcg or ICS/LABA (specific doses not stated)AI-extracted
Key inclusion· 3
  • ✓Diagnosis of asthma (at least two diagnoses documented)
  • ✓Currently on inhaled corticosteroids (ICS) + Tiotropium Respimat 1.25 mcg OR ICS/LABA combination
  • ✓At least 6 months of enrollment prior to starting ICS+Tiotropium or ICS/LABA
Key exclusion· 6
  • ✕COPD diagnosis (at least two diagnoses at any time during study)
  • ✕Age less than 12 years
  • ✕Biologic therapy within 6 months prior to ICS+Tiotropium or ICS/LABA initiation
  • ✕Prior tiotropium or ICS/LABA use during the 6-month baseline period

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05501639
NCT05501639N/ACompleted
CompareCT.gov

Exacerbation Risk in Asthma

Boehringer Ingelheim·observational·Posted Aug 15, 2022·Updated Apr 1, 2024

In Brief

An observational study evaluating tiotropium, long-acting β2-agonists (LABA), and 1 other intervention for Asthma. Completed, enrolled 1,899 participants across 1 site.

Detailed Summary

The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 15, 2022
Enrollment StartMay 14, 2021
Primary CompletionNov 2, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.9 years ago

Interventions

tiotropiumdrug

tiotropium

long-acting β2-agonists (LABA)drug

long-acting β2-agonists (LABA)

inhaled corticosteroids (ICS)drug

inhaled corticosteroids (ICS)